You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

320 Results
Regimen
Intent: Palliative
Funding:
ODB - General Benefit
    exemestane
Exceptional Access Program
    ribociclib - For the treatment of patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER 2)-negative, unresectable locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant according to clinical criteria
Apr 2021
Regimen
Intent: Palliative
Funding:
ODB - General Benefit
    exemestane
Exceptional Access Program
    palbociclib - For the treatment of patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER 2)-negative, unresectable locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant, according to clinical criteria
Feb 2021
Document
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal
Intent: Neoadjuvant
Jan 2024
Guidelines and Advice
Last updated: April 30, 2019 The following information identifies errors and corrections in the Ontario Cancer Statistics 2018 report and supporting...
Mar 2019
Regimen
Cancer Type:
Gastrointestinal, 
Hepatobiliary / Liver / Bile Duct
Intent: Palliative
Apr 2023
Document

Pages